Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Biogen Idec
(NQ:
BIIB
)
186.74
-0.32 (-0.17%)
Streaming Delayed Price
Updated: 1:24 PM EDT, May 4, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biogen Idec
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
59
60
Next >
Should You Buy Biogen Stock After Its Latest Alzheimer's Disease Drug Approval?
↗
January 10, 2023
There's more to the story with Biogen after receiving good news for Leqembi.
Via
The Motley Fool
Barron's Top Weekend Stock Picks: Tesla, Snowflake, Delta And Why Warren Buffett's Berkshire Hathaway May Be In For Big Tax Bill
↗
January 07, 2023
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Via
Benzinga
Longeveron Shares Surge Following FDA Decision on Biogen Alzheimer's Drug
↗
January 06, 2023
Shares of Longeveron (NASDAQ: LGVN) are trading 5.37% higher amid strength in Alzheimer's-related stocks after the FDA granted accelerated approval to Biogen (NASDAQ: BIIB)'s Leqembi.
Via
Benzinga
SAVA, LLY, IBB: Why These Alzheimer's Related Stocks Are Volatile On Friday
↗
January 06, 2023
Stocks of companies with Alzheimer's candidates, including Cassava Sciences, Inc. (NASDAQ: SAVA) and Eli Lilly And Company (NYSE: LLY), spiked on Friday after the FDA granted accelerated approval to
Via
Benzinga
FDA Approves Biogen's Second Alzheimer's Treatment Under Accelerated Pathway
↗
January 06, 2023
Via
Benzinga
1 Large-Cap Biotech Stock to Buy for 2023 and Beyond
↗
January 03, 2023
This company's best asset may be its pipeline.
Via
The Motley Fool
Is Biogen's Stock Too Risky to Invest in?
↗
December 28, 2022
Even at a discount, investors may be taking on a big risk with Biogen.
Via
The Motley Fool
1 Green Flag and 1 Red Flag for Biogen
↗
December 23, 2022
Biogen beat the bear market this year.
Via
The Motley Fool
Lecanemab Alert: What Would Alzheimer’s Drug Approval Mean for Biogen (BIIB) Stock?
↗
January 06, 2023
Biogen is in focus today with the company's lecanemab drug set for an FDA decision on approval, leading to bullish bets on BIIB stock.
Via
InvestorPlace
Top Picks For 2023: Anavex Life Sciences
↗
January 06, 2023
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett...
Via
Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
↗
January 06, 2023
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
Biogen Could Get A Second Alzheimer's OK — But Will Wild Card Medicare Bite?
↗
January 06, 2023
CMS already snubbed Biogen's first Alzheimer's drug. Will the second fare better?
Via
Investor's Business Daily
1 Stock Defying the Downturn to Buy, and 1 to Avoid
↗
January 06, 2023
These two stocks might go in different directions in the future.
Via
The Motley Fool
CRISPR, Genetics And AI — Why 2023 Could Be The Year For Biotech Stocks
↗
January 06, 2023
Genetic medicine is a top theme now for biotech stocks. Other trends are heating up too.
Via
Investor's Business Daily
Could Eli Lilly Stock Help You Become a Millionaire?
↗
January 05, 2023
Over the past 10 years, when including its dividend, Eli Lilly's total return has amounted to an incredible 843%.
Via
The Motley Fool
Biogen Names Priya Singhal as Executive Vice President, Head of Development
January 05, 2023
From
Biogen Inc.
Via
GlobeNewswire
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
January 04, 2023
From
Biogen Inc.
Via
GlobeNewswire
What's Going On With Biogen Stock Today?
↗
December 29, 2022
Biogen Inc (NASDAQ: BIIB) shares traded higher Thursday morning before pulling back. Reports indicate that the FDA's process for approving Biogen's Alzheimer's drug Aduhelm was filled with...
Via
Benzinga
The Battles Brewing That Could Stoke Already Red-Hot Eli Lilly Stock
↗
December 28, 2022
Investors are closely watching two key spaces that could spark Lilly stock.
Via
Investor's Business Daily
The Top Three Stocks Analysts Say To Buy
December 28, 2022
The analysts are rewarding companies that prove they can succeed in the face of headwinds and the most upgraded in Q4 2022 are Netflix, Biogen and Nike.
Via
MarketBeat
Biogen's 2nd Alzheimer's Antibody, BeiGene's Cancer Drug Label Expansion, Adcom Test For Regeneron And More: January PDUFA Catalysts For Biotech Investors
↗
December 27, 2022
Biopharma stocks were not immune to the broader market downturn seen for much of 2022.
Via
Benzinga
Roche's Follicular Lymphoma Therapy Scores FDA Approval
↗
December 23, 2022
Via
Benzinga
3 Nasdaq Stocks That Are Up 25% in 3 Months
↗
December 23, 2022
Should you jump on the bandwagon and buy these surging stocks?
Via
The Motley Fool
Biogen's Alzheimer's Antibody Might Have A Third Death Associated With
↗
December 22, 2022
A third death is supposedly linked with Biogen Inc's (NASDAQ: BIIB) investigational Alzheimer's antibody, lecanemab.
Via
Benzinga
Has This Top Pharma Company Found Its Next Billion-Dollar Product?
↗
December 22, 2022
Eli LIlly is looking to make waves in an important therapeutic area.
Via
The Motley Fool
Top Biotech Companies Are Making Steady Progress In Developing Treatments To Fight Alzheimer’s Disease
↗
December 21, 2022
The estimated cost of Alzheimer's disease and related dementia (ADRD) care in 2021 was $355 billion. Investing in the top companies that are making steady progress toward developing a treatment for...
Via
Talk Markets
Biogen Reaches Agreement with Genentech to Receive Royalties on the Potential Commercialization of a Late-Stage Bispecific Antibody as Part of Anti-CD20 Collaboration
December 19, 2022
From
Biogen Inc.
Via
GlobeNewswire
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
↗
December 18, 2022
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.
Via
InvestorPlace
Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move
↗
December 18, 2022
These stocks have climbed by double digits this year.
Via
The Motley Fool
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock
↗
December 18, 2022
Both stocks are heading for double-digit gains this year.
Via
The Motley Fool
< Previous
1
2
...
29
30
31
32
33
34
35
36
37
...
59
60
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
